2014
DOI: 10.1016/j.ejca.2013.12.017
|View full text |Cite
|
Sign up to set email alerts
|

Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
13
0
2

Year Published

2014
2014
2020
2020

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 23 publications
(16 citation statements)
references
References 3 publications
1
13
0
2
Order By: Relevance
“…The rate of PSA responses to Enz (≥50% PSA decline) as a fourth- or fifth-line therapy is similar to the 12.8 and 39.1% response rates reported in patients treated with Enz as a third-line therapy [9,10,11,12,13,14,18]. These rates are significantly lower than the 54% response rate reported in the AFFIRM trial, where patients were treated with Enz after progressing on Doc [4].…”
Section: Discussionmentioning
confidence: 55%
See 3 more Smart Citations
“…The rate of PSA responses to Enz (≥50% PSA decline) as a fourth- or fifth-line therapy is similar to the 12.8 and 39.1% response rates reported in patients treated with Enz as a third-line therapy [9,10,11,12,13,14,18]. These rates are significantly lower than the 54% response rate reported in the AFFIRM trial, where patients were treated with Enz after progressing on Doc [4].…”
Section: Discussionmentioning
confidence: 55%
“…These data suggest that the optimal sequence of treatment options is individual. Relatively small retrospective studies reported on the activity of Enz as a third-line treatment after Doc and Cab or AA [9,10,11,12,13,14,18]. However, there is limited data on the efficacy of Enz as a fourth- or fifth-line treatment.…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…Появился энзалутамид -антиандроген второго поко-ления, который блокирует все три этапа сигнального пути в опухолевой клетке: связывание андрогенов с АР, транс-локацию АР в ядро, связывание АР с ДНК и активацию транскрипции [5].…”
Section: Introductionunclassified